Zobrazeno 1 - 10
of 99
pro vyhledávání: '"Rozeman, E.A."'
Autor:
Rawson, R.V., Adhikari, C., Bierman, C., Lo, S.N., Shklovskaya, E., Rozeman, E.A., Menzies, A.M., van Akkooi, A.C.J., Shannon, K.F., Gonzalez, M., Guminski, A.D., Tetzlaff, M.T., Stretch, J.R., Eriksson, H., van Thienen, J.V., Wouters, M.W., Haanen, J.B.A.G., Klop, W.M.C., Zuur, C.L., van Houdt, W.J., Nieweg, O.E., Ch'ng, S., Rizos, H., Saw, R.P.M., Spillane, A.J., Wilmott, J.S., Blank, C.U., Long, G.V., van de Wiel, B.A., Scolyer, R.A.
Publikováno v:
In Annals of Oncology June 2021 32(6):766-777
Autor:
Jansen, Y.J.L. *, Rozeman, E.A., Mason, R., Goldinger, S.M., Geukes Foppen, M.H., Hoejberg, L., Schmidt, H., van Thienen, J.V., Haanen, J.B.A.G., Tiainen, L., Svane, I.M., Mäkelä, S., Seremet, T., Arance, A., Dummer, R., Bastholt, L., Nyakas, M., Straume, O., Menzies, A.M., Long, G.V., Atkinson, V., Blank, C.U., Neyns, B.
Publikováno v:
In Annals of Oncology July 2019 30(7):1154-1161
Autor:
Trebeschi, S., Drago, S.G., Birkbak, N.J., Kurilova, I., Cǎlin, A.M., Delli Pizzi, A., Lalezari, F., Lambregts, D.M.J., Rohaan, M.W., Parmar, C., Rozeman, E.A., Hartemink, K.J., Swanton, C., Haanen, J B A G, Blank, C.U., Smit, E.F., Beets-Tan, R.G.H., Aerts, H.J.W.L *
Publikováno v:
In Annals of Oncology June 2019 30(6):998-1004
Autor:
Meerveld-Eggink, A., Rozeman, E.A., Lalezari, F., van Thienen, J.V., Haanen, J.B.A.G., Blank, C.U. *
Publikováno v:
In Annals of Oncology April 2017 28(4):862-867
Autor:
Madu, Max F., Rozeman, E.A. Lisette, van der Hage, Jos A., Wouters, Michel W.J.M., Klop, W. Martin C., van Thienen, J.V. Hans, Blank, Christian U., Haanen, John B.A.G., van Akkooi, Alexander C.J.
Publikováno v:
In Clinical Skin Cancer January 2016 1(1):48-52
Autor:
Rozeman, E.A., Versluis, J.M., Moritz, R., Wilgenhof, S., Thienen, J.V. van, Haanen, J.B.A.G., Heuvel, M.M. van de, Blank, C.U., Rossum, H.H. van
As a subset of advanced melanoma patients derive long-term benefit from anti-PD-1 therapy, early identification of non-responsiveness would enable an early switch to next line therapies. This study assessed if an early increase in S100B or lactate de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______202::74559060cacad62ee9a1c4a1d65313e4
https://hdl.handle.net/1887/3627563
https://hdl.handle.net/1887/3627563
Autor:
Versluis, J.M., Reijers, I.L.M., Rozeman, E.A., Menzies, A.M., Akkooi, A.C.J. van, Wouters, M.W., Ch'ng, S., Saw, R.P.M., Scolyer, R.A., Wiel, B.A. van de, Schilling, B., Long, G.V., Blank, C.U.
Publikováno v:
European Journal of Cancer, 148, 51-57. ELSEVIER SCI LTD
Background: Patients with synchronous clinical stage III melanoma can present with primary melanoma lesions, locally recurrent melanoma or in-transit metastases. Neoad-juvant ipilimumab plus nivolumab induces high pathologic response rates and an imp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::1fde8b660487a3300247bf460369d7bd
https://hdl.handle.net/1887/3276135
https://hdl.handle.net/1887/3276135
Autor:
Hoeijmakers, L., Rozeman, E.A., Lopez-Yurda, M., Grijpink-Ongering, L., Heeres, B., van de Wiel, B., Flohil, C., Sari, A., Heijmink, S., Van Den Broek, D., Broeks, A., de Groot, J.W., Vollebergh, M., Wilgenhof, S., van Thienen, H.V., Haanen, J.B.A.G., Blank, C.U.
Publikováno v:
In Annals of Oncology October 2023 34 Supplement 2:S670-S670
Autor:
Lucas, M.W., Rozeman, E.A., Versluis, J.M., Menzies, A.M., Eriksson, H., van de Wiel, B., Scolyer, R., van Thienen, H.V., Mallo, H., Gonzalez, M., Landman, L., Torres Acosta, A., Grijpink-Ongering, L., Haanen, J.B.A.G., van Akkooi, A.C.J., Long, G.V., Blank, C.U.
Publikováno v:
In Annals of Oncology October 2023 34 Supplement 2:S660-S661
Autor:
Boekhout, A.H., Rogiers, A., Jozwiak, K., Boers-Sonderen, M.J., Eertwegh, A.J. van den, Hospers, G.A., Groot, J.W.B. de, Aarts, M.J.B., Kapiteijn, E., Tije, A.J. ten, Piersma, D., Vreugdenhil, G., Veldt, A.A. van der, Suijkerbuijk, K.P.M., Rozeman, E.A., Neyns, B., Janssen, K.J., Poll-franse, L.V. van de, Blank, C.U.
Background: Checkpoint inhibitors have changed overall survival for patients with advanced melanoma. However, there is a lack of data on health-related quality of life (HRQoL) of long-term advanced melanoma survivors, years after treatment. Therefore
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_____10693::b46188c36dd191dd0d4ca7767d656e54
https://hdl.handle.net/1887/3195919
https://hdl.handle.net/1887/3195919